Videos
Cesca Therapeutics CFO and Director of Clinical Affairs Discuss Investment Opportunities
Cesca Therapeutics CFO and Director of Clinical Affairs Discuss Investment Opportunities
Merger and clinical trials highlighted at ARM Investor Conference.
By Alliance for Regenerative Medicine04.25.16
Presented by: Mike Bruch, CFO; and Dalip Sethi, Ph.D., director, Clinical Affairs.
Cesca Therapeutics is engaged in the research, development and commercialization of cell-based therapeutics for use in regenerative medicine. The Company focuses on three target markets to serve patients, physicians and partners: Cellular Therapeutics; Medical/Diagnostic Device Development and Commercialization; and Cell Manufacturing and Banking. Cesca’s lead therapeutic technology platform, SurgWerks (an intraoperative rapid system for harvesting, selection/purification, testing and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia and orthopedic injuries. Cesca’s therapies are designed for rapid (60-90 minute) use and per U.S. regulations include all integrated equipment to produce the specified autologous therapeutic cell dose. The Company’s therapeutic platform is built upon decades of experience in engineering and development of biologic device technologies and Cesca’s approach is protected through a comprehensive device design and patent portfolio.
Related Searches:
